Geneseeq advanced its fragmentomic cell-free DNA approach with Fragmentia-AI, an AI model designed to read DNA fragment patterns as a language rather than relying only on mutation lists and fragment lengths. In a Cell Reports Medicine pilot, the approach showed multi-cancer detection capability across sequencing protocols and low-variant settings using ultra-low-pass whole-genome sequencing. The company positioned Fragmentia-AI for early cancer detection, MRD monitoring, and post-treatment risk stratification, emphasizing generalizability across tumor types—even when initially trained on a targeted gene panel from lung cancer. If validated in larger clinical studies, fragmentomic modeling could improve signal utilization in liquid biopsy workflows by extracting information from the typically underused non-mutant fragment data in plasma.